Edgewise Therapeutics, Inc.
EWTX evidence brief
What we can confirm
- BioSniper Score:
- 4.3 / 10
- Market Cap:
- $4.76B
- Lead Asset:
- EDG-7500 (Phase 1)
What it means
What to watch
Prepared research question
What matters most for EWTX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · EWTX
Edgewise Therapeutics, Inc. (EWTX) is a late-stage clinical biopharmaceutical company focused on developing precision medicines for severe muscle diseases, with a proprietary platform targeting skeletal and cardiac muscle.
Key risk: Clinical trial failure
BioSniper Score
Based on 4 of 6 signals
Market Cap
$4.76B
Cash Runway
—
Lead Asset
EDG-7500 (Phase 1)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 10 clinical trials for Edgewise Therapeutics, Inc..
Edgewise Therapeutics, Inc. (EWTX) is a late-stage clinical biopharmaceutical company focused on developing precision medicines for severe muscle diseases, with a proprietary platform targeting skeletal and cardiac muscle.
- Edgewise is a late-stage clinical biopharmaceutical company focused on severe muscle diseases, leveraging a proprietary muscle-focused drug discovery platform [sec · filed 2026-04-23].
- In May 2026, Edgewise entered an Asset Purchase Agreement to sell sevasemten and its muscular dystrophy program to Servier for $1,550 million upfront and up to $1,100 million in milestones, completed on July 10, 2026 [sec_mda · as of 2026-08-06].
- As of 2026-06-30, the company reported cash & equivalents of $72.3M, net income of -$57.3M, and shareholders' equity of $448.1M [sec].
- The cardiovascular pipeline includes EDG-7500 (Phase 2 for hypertrophic cardiomyopathy) and EDG-15400 (Phase 1 for heart failure with preserved ejection fraction) [sec_mda · as of 2026-05-07].
- Key near-term catalysts include CIRRUS-HCM 12-week data for EDG-7500 in H1 2026 and pivotal GRAND CANYON results for sevasemten in Becker muscular dystrophy expected in Q4 2026 [news · published 2026-02-26].
What works
- Edgewise completed a major asset sale of sevasemten to Servier for $1,550 million upfront, providing substantial non-dilutive capital to fund ongoing programs [sec_mda · as of 2026-08-06].
- The company has a diversified pipeline addressing both skeletal muscle (muscular dystrophies) and cardiac muscle (HCM, HFpEF) indications [sec_mda · as of 2026-05-07].
- Multiple late-stage clinical trials are underway, including a pivotal cohort for sevasemten in Becker muscular dystrophy (GRAND CANYON) and a Phase 2 trial for EDG-7500 in HCM [news · published 2026-02-26].
What to weigh
- The company reported a net loss of -$57.3M for the six months ended 2026-06-30, reflecting high R&D and operational costs [sec].
- Edgewise's future revenue depends on regulatory and commercial milestones from the sevasemten sale, which are uncertain and contingent on achieving sales thresholds [sec_mda · as of 2026-08-06].
- The company faces typical biotech risks including clinical trial failures, regulatory delays, and increased expenses as it advances its pipeline [sec_mda · as of 2026-08-06].
From the filings
Quoted directly from source documents.
Edgewise sold sevasemten to Servier for $1,550 million upfront.
“we entered into an Asset Purchase Agreement under which Servier Pharmaceuticals LLC and Les Laboratoires Servier (Servier) acquired sevasemten and our muscular dystrophy program for $1,550 million in upfront cash consideration”
SEC MD&A · August 6, 2026
Edgewise is a late-stage clinical biopharmaceutical company focused on severe muscle diseases.
“We are a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe muscle diseases.”
SEC filings · April 23, 2026
CIRRUS-HCM 12-week data for EDG-7500 expected in H1 2026.
“CIRRUS-HCM 12-week data of EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) expected in H1 2026”
News · February 26, 2026
Pivotal GRAND CANYON results for sevasemten in Becker expected in Q4 2026.
“Pivotal GRAND CANYON results for sevasemten in Becker muscular dystrophy (Becker) expected in Q4 2026”
News · February 26, 2026
Risks & what to watch (3)›
Key risks
- Clinical trial failure — Late-stage trials (e.g., GRAND CANYON, CIRRUS-HCM) may fail to meet endpoints, harming pipeline value [news · published 2026-02-26].
- Milestone dependency — Future revenue from sevasemten sale relies on achieving regulatory and commercial milestones up to $1.1B [sec_mda · as of 2026-08-06].
- Cash burn rate — Net loss of $57.3M in H1 2026 with cash of $72.3M as of 2026-06-30 may require additional financing [sec].
What to watch
- CIRRUS-HCM 12-week data for EDG-7500 in H1 2026 [news · published 2026-02-26].
- Phase 1 healthy adult trial data for EDG-15400 and plans for heart failure studies in H1 2026 [news · published 2026-02-26].
- Pivotal GRAND CANYON results for sevasemten in Becker muscular dystrophy expected in Q4 2026 [news · published 2026-02-26].
- Initiation of Phase 2 trial for EDG-15400 in HFpEF in second half of 2026 [sec_mda · as of 2026-05-07].
Sources: Catalysts · News · SEC filings · SEC MD&A · Generated October 7, 2026 · How we verify sources →
Run Edgewise Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Edgewise Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.07 · 0% dilution
Lead: Phase 1
1 candidate
No upcoming catalysts tracked
0 buys · 23 sells (180d)
Pipeline
Regulatory
Financials
Short Interest
as of Apr 19, 2026- % of float
- 10.3%
- Days to cover
- 10.7
- Shares short
- 9,448,351
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
EWTX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Edgewise Therapeutics, Inc.?
Edgewise Therapeutics, Inc. (EWTX) is a late-stage clinical biopharmaceutical company focused on developing precision medicines for severe muscle diseases, with a proprietary platform targeting skeletal and cardiac muscle.
What is Edgewise Therapeutics, Inc.'s lead drug candidate?
Edgewise Therapeutics, Inc.'s most advanced tracked candidate is EDG-7500 (Phase 1) for Healthy Adult Participants; Hypertrophic Cardiomyopathy; Renal Impairments.
Who is the CEO of Edgewise Therapeutics, Inc.?
Dr. Kevin Koch Ph.D. is the chief executive officer of Edgewise Therapeutics, Inc. (EWTX).
Where is Edgewise Therapeutics, Inc. headquartered?
Edgewise Therapeutics, Inc. (EWTX) is headquartered in Boulder, CO, United States.
What therapeutic areas does Edgewise Therapeutics, Inc. focus on?
Edgewise Therapeutics, Inc. develops therapies across Rare Disease, Gene Therapy, Cardiovascular, Nephrology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.